Bilirubin Oxidation Products and Cerebral Vasoconstriction

Key evidence in support of the hypothesis that bilirubin oxidation products (BOXes) contribute to the vasoconstriction associated with subarachnoid hemorrhage (SAH) are the (1) presence of BOXes in cerebral spinal fluid from SAH patients and (2) ability of one or more BOXes to elicit vasoconstrictio...

Descripción completa

Detalles Bibliográficos
Autor principal: Rapoport, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934420/
https://www.ncbi.nlm.nih.gov/pubmed/29755343
http://dx.doi.org/10.3389/fphar.2018.00303
_version_ 1783320109940473856
author Rapoport, Robert M.
author_facet Rapoport, Robert M.
author_sort Rapoport, Robert M.
collection PubMed
description Key evidence in support of the hypothesis that bilirubin oxidation products (BOXes) contribute to the vasoconstriction associated with subarachnoid hemorrhage (SAH) are the (1) presence of BOXes in cerebral spinal fluid from SAH patients and (2) ability of one or more BOXes to elicit vasoconstriction. We critically evaluate this key evidence, detail where gaps remain, and describe recent approaches that will address these gaps.
format Online
Article
Text
id pubmed-5934420
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59344202018-05-11 Bilirubin Oxidation Products and Cerebral Vasoconstriction Rapoport, Robert M. Front Pharmacol Pharmacology Key evidence in support of the hypothesis that bilirubin oxidation products (BOXes) contribute to the vasoconstriction associated with subarachnoid hemorrhage (SAH) are the (1) presence of BOXes in cerebral spinal fluid from SAH patients and (2) ability of one or more BOXes to elicit vasoconstriction. We critically evaluate this key evidence, detail where gaps remain, and describe recent approaches that will address these gaps. Frontiers Media S.A. 2018-04-27 /pmc/articles/PMC5934420/ /pubmed/29755343 http://dx.doi.org/10.3389/fphar.2018.00303 Text en Copyright © 2018 Rapoport. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Rapoport, Robert M.
Bilirubin Oxidation Products and Cerebral Vasoconstriction
title Bilirubin Oxidation Products and Cerebral Vasoconstriction
title_full Bilirubin Oxidation Products and Cerebral Vasoconstriction
title_fullStr Bilirubin Oxidation Products and Cerebral Vasoconstriction
title_full_unstemmed Bilirubin Oxidation Products and Cerebral Vasoconstriction
title_short Bilirubin Oxidation Products and Cerebral Vasoconstriction
title_sort bilirubin oxidation products and cerebral vasoconstriction
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934420/
https://www.ncbi.nlm.nih.gov/pubmed/29755343
http://dx.doi.org/10.3389/fphar.2018.00303
work_keys_str_mv AT rapoportrobertm bilirubinoxidationproductsandcerebralvasoconstriction

Ejemplares similares